DASTY Dassault Systèmes SE

OTC
$25.77

Dassault Systèmes SE Q3 F2026 Earnings Call Transcript

AI Conference Call Analysis

Sign in or subscribe to read.
Marie
Investor Relations
Good morning and thank you for joining our third quarter 2026 earnings conference call and in Dastan in London. I'm with Pascal Daloz, Chief Executive Officer and Chairman of Dassault Systèmes and Rouven Bergmann, Chief Financial Officer to discuss our third quarter 2026 results. Dassault Systèmes results are prepared in accordance with IFRS, the financial figures discussed are well noted. Some of the comments contain forward-looking statements that could differ materially from actual results. Please refer to today's press release in the risk factor section of our 2025 Universal Registration Document and all earnings materials are available on our website. These pre-fabric marks will be available shortly after this call. So now over to you Pascal.
Pascal Daloz
Chief Executive Officer and Chairman
Merci Marie. So good morning to all of you and thank you for being here. and especially for the one who are physically here in the room with us, I always appreciate to have this live interaction with you. I think before Rouven takes you through the number, I really want to start by giving you the big picture. It's about what we are building and why it matters for the next era of the industry. You know, at the start of the year, you remember, We call the 2026 a foundational year. I think it's a year where... How can I say that? It's not a year of waiting, it's a year of building. Building a new category of products, building an AI native platform, developing partnerships, all in services of the growth. And I think for more than 20 years, we have helped industries to connect both worlds, the virtual world and the real world, for them to be able to imagine, design and test. And now, I think at the age of AI, this connection matters more than ever. Why so? Because generating an answer is not enough. You know, you need to create a design, simulated, tested, validated, manufactured, often certified, before it could fly, before it could be on the market. So, whatever is a powerful model you have in your hand, it's not enough. And you need engineering context around it. You need connected environments where AI can be tested against the behavior of the real world. So this is the role of our Gifle twins, our industry world model, to ground AI in science and in the behavior of the physical world. And this is why also 3D experience is evolving into an adjuncting platform, because we are bringing AI together with industrial knowledge and human expertise, so intelligence can move from generating ideas to helping to deliver trusted outcomes. Now, let's start with the performance of Q3. And why this is important? Because I think execution matters. You remember that's what I said last quarter. I think we deliver a strong execution at the high end of our objectives. You saw it, total revenue grew 5%, software revenue grew 5 as well, 3D experience platform plus 25, cloud plus 14%, EPS reached 32 cents, up 8%. But I think, and the revenue growth is now expected to be between 4 to 5%, up from 3 to 5, and the EPS growth is now expected to be between 6 to 7, up from 3 to 6%. So, Alice Global is obviously part of the updated outlook and Rouven will walk through the assumptions and the financial details for you. Behind this number, I think there are some priorities which are driving the progress. The first one is we are helping our existing customers to transform their businesses. and to turn industry pressure into opportunity and you can see the 3DEXPAM platform and the cloud continue to perform strongly this quarter. The most important, we are also winning new customers and this not only in one given industry or in one given geo, it's really broad-based. The second priority is we are taking a major step forward in life sciences. Bringing Artists Global into the portfolio, building towards a unified AI native platform and putting a dedicated leadership in place. And I know it's a topic some of you asked many times how we will integrate all the pieces together and I will come back on this. The third one is we are expanding 3D universe to turn AI advances into practical industrial value. We see this every day in our work with customers. and we will share a few great examples, the one we saw at the Paris Auto Show or the GTC Berlin last week. Just remember one thing, our strategy is very clear, we deliver today and we build for the next wave and we connect the two. This is really the most important and this is what we have done this quarter. And the momentum is really across many many industries, high tech, industrial equipment, automotive. And the next steps for them is not only to serve their local market but is really to industrialize those innovations to bring them to the global market. And we see this similar shift in many industries, robotics, pharmaceuticals, aerospace, where complexity is increasing and the ability to connect the disciplines matter more than ever. Take Comac, the China leading commercial air manufacturers as an example. Their mission is really simple, to bring its first large wide-body aircraft to the global market. And to make this happen, COMAC needs to industrialize the programs, needs to secure the certifications, to get ready to bring the aircraft to the market, and again, both in China, but more importantly, internationally. And that's the key, because the global market needs to be part of the plan from day one. Not something you think after and you put it later. So this is where we enter into the game because with 3DEXPERIENCE platform we bring design, system engineering, simulation, manufacturing, planning in one unified environment, giving everyone a shared view of the program. And with the model-based system engineering, you know, teams can tackle the complexity very early on. and when changes are easier, less costly to make and decisions can have almost no impact. That's how we are helping our customers to manage complex programs and turn the global emissions into the reality. Now, let's look at life sciences. Good news, we start to see some positive signs. You know, Pharma and Biotech are picking up. You have seen like And that's an important point because last time we saw this was at the COVID time. So that's number one. Number two, we are also seeing since improving quarter over quarter at MediData. MediData is flat and again, we come back on this and we expect to return to growth in Q4. Another encouraging sign is that the customers are increasingly seeing the value of our platform approach. We saw this in Q1 with one of the large deals we signed with WCT, Worldwide Clinical Trial. And now we are seeing something similar with NREST. And the idea is very simple. Instead of using different tools for every clinical trial, we give the CRO one AI platform to manage their clinical operations. And the benefits are very clear. The team can work much more efficiently and get better in the diversification industry, which grew at a double-digit rate this quarter. We are searing a very strong momentum, especially in high-tech and around AI infrastructure. You remember we have built expertise in the nuclear a few years ago, which was and still one of the most complex systems to engineer. And I think now we are putting that expertise to work in another equally demand area, which is this AI infrastructure. And because the AI factory is much more than a room full of GPUs, you need compute, networking, power, cooling, Software and all those things need to work together and when you change one element it could affect everything else. So you need to think about the whole systems from day one and to be ready to adapt when things are evolving and you know the cycle of obsolescence is such that things are evolving almost on a monthly basis. First for the data centers and today these different elements are often designed separately. So what do we do with our virtual twin? We bring all of them together, to design them together, to simulate them together, how they will work as one system before anything is deployed. And the goal is very important, is get AI infrastructure up and running faster and reduce the time for the first tokens. That's the motto, reduce the time for the first token. That brings us back to the big picture. because as AI becomes more complex, we can fly against the same system level engineering expertise we have developed in some of the world's most demanding industries. And this is becoming, I would say, on top of the agenda of many of the CEOs who are in this business because for, in general, and now the constraint that all the other industries have to basically be on time, on quality, on cost, On Purpose. You know, we need to apply the techniques we learned from the other industries. And this is where we are stepping in. Now, let's take a little bit of step back and look at the kind of product industries are starting to create. Think about intelligent robots, autonomous vehicles, smart wearables. You know, they are not just traditional products with AI on top of it. They are entirely new kind of products and that changed the way we need to design them. So remember this, most of you are challenges how we are integrating AI in what we do, but the real question is not this one, is how we are evolving to basically support this industry when they are becoming AI native. And with AI native products, intelligence is built from the start. to the physical world and to make sure that it really works. That's what 3D Universe is all about. Connecting intelligence, digital intelligence, to the physical world and it proves and proves that it works. So to do this, we combine industrial know-how with science and AI to create industry world model and virtual twin at scale. In practical terms, what does it mean? It means industry can try out different ideas, see what might happen, test their decision virtually before taking action in the real world. And there is an important point here. In industry, you know, being intelligent is not enough. You also need to trust the results. And that's the reason why we are different. because we bring again science and industrial knowledge into AI so we can explain the results, test them, and validate them. Let me give you two very simple examples. AI can describe very easily an aircraft wings, but cannot design it, and more importantly, cannot certify the wing. It can summarize a clinical trial protocol, but that does not mean it can be validated. So there is a big difference between the formulations and basically or being right are very two different notions. That's why AI needs an environment where it can learn, test against the rules of the real world. And that's exactly what our virtual twins and our industry world model provides. But to this we will come back much more in details at our Capital Market Day. We also are seeing this shift to take place. Remember, in July, we made 3DEXPERIENCE Platform Exantic. We introduced all the virtual companions. You know them, Léo, Marie, Aura, Louis. They have some specific skills. Skills need to work alongside with the people. Now, what do we do? We are exploring with the early AI adopters across industries, across, around the world, you know from AI native startups to some of the big global players and so far you can see on the slides we have around 100 strategic customer partnerships working with us and we are developing industrializing the use cases now the focus is really on taking this early success to the next level and this is what we're going to do in 2027 we plan to scale up Moving from the promising use cases to solutions can be deployed more broadly repeatedly across the customers. Let me give you a more vessel companion. You know, they can take on tasks, work together and bring the right virtual or human experts when it's needed. And the most important thing is they don't just answer the questions. They can actually get work done. drawing on specific skills, industrial knowledge, and they keep the people in control. So here you have a good example, which is what we are doing at Volkswagen. Therefore, companions are helping engineering teams to streamline their workflows and get things done much more efficiently. So we start with Aura as a coordinator. Aura is bringing action plans together, assign tasks, Leo explores the design options based on the Volkswagen's engineering heritage data sets. And they share, Leo shares the results with Aura. And when Aura can review those results, adjust the plans, keep the track in what is happening next. So throughout the process, again, the people remain in control and accountable for the decisions. So the real value is not just automating the task. is getting different skills to work together against industrial knowledge and human overseeing, if you want. It's humanoid robots for Audi with agile robots. Here is an interesting case because this is really the physical AI in action. Leo used our industrial world models to create the virtual twin of the factory. The robots, you know, they have their own virtual twins, too. But what does it mean? It means it allows the teams to explore how the two will behave together in one virtual environment, reflecting the real-world physics. And this is what it gets interested in, assess the cycle times, see how production throughput will be affected. And they can work through these questions virtually before anything goes on the shop floor. And the results, and we have now a lot of KPIs, Fewer unknowns, better informed decisions, much more confidence, and more importantly, the time to deploy. Because at the end, it's how you speed up the commissioning. So, what is in common between the two strengths, between the two examples I shared with you? Is really, we can explore and learn and validate the virtual world before taking illogical AI. And in fact, we are doing the same thinking process, but to a different challenge. And the stakes are especially high because ultimately it's about human health and patient outcomes. So, too often, and now you start to know it, what we learn in the real world does not fly back quickly enough to inform the next scientific discovery. And in fact, losing this gap is one of the biggest opportunities we see in life sciences. and this quarter you know we took an important step in these directions with the completion of the acquisition of ARIS Global. But you know it's much more than adding the drug safety capabilities. It's about connecting the pharmaceutical journey and the formula is released from the molecule to patients to the real world evidence and then bring what we learn platform helping the life science company, biotech, big pharma, to turn those real worlds inside into the next wave of scientific progress. To make this ambition real, we are putting a new operating model in place. In fact, we are bringing together expertise across all the disciplines, clinical developments, discovery, labs, manufacturing, regulation compliance, real-world safety, medical practice also. And we are unifying this capability with our 3DX adjuncting platform. And we streamline the go-to markets. And the goal is very straightforward. It's one coordinated organization, one integrated offer, a simple way for our customers to get access to the solution they need. But to do this, I'm also pleased to welcome Dr. Ashimini Zenous to Dassault Systems. Ash is a physician and a technology entrepreneur and she has a very strong background in digital health and AI. And what makes her background particularly valuable is the fact that she brings together the two worlds, the world of the medicine and the world of the technology. And this is exactly the combination we need to bring our ambitions to life. So our role will be to lead the strategy, bring Medidata, Biovia, ARIS Global together in one AI native platform, connecting molecules, patients, real-world outcomes, and again, closing the loop back to science. She will lead the life science healthcare as one business with a clear focus on the science-driven innovations, the operational excellence, building ever stronger relationships with our customers and partners. So, what about her visions for the business? Now, the mission of this integrated organization is also very simple. You know, the entire purpose of Dassault Systèmes is not to only improve the productivity and to streamline the workflow. It's to inspire smarter treatment for healthier people. And why this is important? Because at the very core of everything we do, you have the patient. Just think about the reach today. Our solution, supporting 15 million patients in a single trial. 16 million patients in the real world. to collect those real-world evidence. And the medicines which are tested, and the COVID vaccine is one of the examples, is used to reach more than 6 billion people on Earth. So that's the dedication of these organizations. We are also covering half of the safety even worldwide across a wide range of therapies and treatment types. And you know, those numbers are telling you a very important story. They show the scale of the ecosystem we are building. And behind the scale, you have more than 5,000 colleagues. Many of them have a PhD, doctors. They are knowledgeable on the therapeutic domains, on the modality of the machines. More than basically only the, you know, the two nodes working closely with the regulators in Europe, in United States, in Asia. We also have built a rich foundation with experience across 42,000 clinical trials and 2 million safety events every year. And why all of this matters? Because when it comes to AI in life sciences, scale and expertise really make the difference They help us to build AI. This is grounded in science and reflects the reality of the industry. So this is an important point, distinction, to keep in mind. In manufacturing, physics sets the rules. In life sciences, biology is the one. And biology is incredibly complex. You can understand by looking at the document. Basically, we can make the process faster or more efficient. It's really about helping the sciences to make new discoveries, advance treatments, and most importantly improve the outcome for patients. So we look forward to share more with you at our Capital Market Day in Paris in November 2017. And before to hand over to Rouven, let me sub up a few messages for you. We are making good progress in our priority, which gives us the confidence in our updated full year objectives. We are also moving from our AI roadmaps to the real-world adoptions and we are taking an interpersonal step forward in licenses. With that, Rouven, the floor is yours.
Rouven Bergmann
Chief Financial Officer
Thank you Pascal and also a warm welcome to you here. in London joining us in person and also good morning to you online. So as Pascal, as you mentioned, we enter the final stretch of the year with momentum. Our focus remains squarely on the execution of our growth model and on delivering our objectives. The annual run rate is up 6% as your revenue growth is at 5%. and it's at the top end of our objectives that we had set for the quarter. The operating margin expanded by 150 basis points to 31.6% for the quarter. It's well above our objectives and the operating profit was 10% year-on-year. So the strong profitability is converting into cash with cash conversion now reaching 111% year-to-date and this is driving an EPS growth of 8% and an operating cash flow growth of 20% year-to-date. So in short, we are stepping up the execution as we head into the close of the year. Now let's take a deeper look into the financials of the quarter. The total revenue reached 1,552,000,000. It's up 5%. The subscription revenue up 6% in the quarter and year-to-date and licenses growing at 14%. This license growth reflects a robust performance, a strong performance in China and it also compares to a lower baseline versus last year. Highlights to progress in our business model transition. This quarter we are reaching an important milestone because our subscription revenue now represents 50% of our recurring revenue and service revenue was up 7%. and this top line leverage continued and continued operating discipline translated into an uplift of 10% in operating profit with a margin of 31.6% which is up 150 basis points XFX.
Pascal Daloz
Chief Executive Officer and Chairman
EPS was 32 cents and scoring at 8% XFX.
Rouven Bergmann
Chief Financial Officer
Year to date this brings us to 4,617,000,000 in total revenue is scoring 4% with a solid expansion of the operating margin of 80 basis points. and EPS is now 93 cents year-to-date and is up a healthy 7% x-effects. So in summary, this quarter revenue reached the top end of our expectations while operating margin and EPS surpassed them. Now looking more closely at our recurring business growth. In the quarter we sell ARR to 4,505,000,000 or a growth of 6%. But what's important to highlight and must be understood is that the subscription run rate continues to accelerate quarter on quarter and it's now moving towards mid-teens and this is what's driving the underlying strength in ARR and the momentum. Importantly as of Q3 the subscription run rate now accounts for half of the annual run rate and it's up from 46% at that time of Q3 last year. So we've been adding one point of share per quarter since Q3 of last year. This is why it's an important milestone because it's shifting our business model further towards growth acceleration. So equally we saw continued growth in cloud bookings and the contribution from multi-year subscription deals with high-end cloud together in our core industrial business with Centric and Medidata all generating sequential growth contribution. The top 15 deals accounted for about 80% of the net increase in subscription annual run rate. Now let's turn to the growth drivers. 3DEXPERIENCE rose 25%, Cloud up 14% in the third quarter. And 3DEXPERIENCE Cloud, now our core business, growing 46% and is pretty consistent for the quarter and year to date. The growth in 3D experience and cloud, as you heard by Pascal, reflects strong customer demand and increasing focus on transformation, on transforming the operation and for the preparation of industrial AI at scale. 3D experience connects our customers' data, the applications they use and the knowledge they have. With AI we are virtualizing the real worlds, leveraging virtual twins to provide intelligence to engineers, scientists and business users. Our agentic platform and this quarter clients such as EDF, Mahindra Mahindra, Eaton, Emra Rea, Versiv among others, they highlight this momentum in progress.
Pascal Daloz
Chief Executive Officer and Chairman
Now let's take a look at the geo performance.
Rouven Bergmann
Chief Financial Officer
Looking across the geos, Asia was excellent with a growth of 12%. It was led by strong growth in China. Euro performance was resilient, scoring at 9% in the quarter. In America, the execution was well, however, the growth was down by minus 3% due to a tough year-over-year comparison. Now to performance in China. We saw good momentum in aerospace, including Comac, as you mentioned, Pascal, as well as strong winds in the high-tech sector. In Europe, it's a healthy growth and it was driven by renewals mainly in the UK and France. However, we also offset some softer performance in Southern Europe and Central Europe. From an industry perspective, the performance was support-based. It was supported by good momentum with strong growth in 3D experience as well as subscription. As mentioned, the Americas was negative growth, minus 3%. It's the result of tough comps when we look at high-tech and industrial equipment are performing and growing well. Our growth drivers performed well with strong growth in cloud in the Americas region. And important to highlight is that we are advancing fast with strategic clients, creating concrete plans to adopt our Gen7 portfolio. Vertiv is an excellent example highlighting the potential that Gen7 creates and it helps us to expand our reach in new industries building sustainable AI factory infrastructure.
Pascal Daloz
Chief Executive Officer and Chairman
So overall the Americas is more back-end loaded than other GEOs this year and I think this is important to keep in mind.
Rouven Bergmann
Chief Financial Officer
Now let's move to our performance by product line. Industrial innovation grew a strong 5% and it had this strong com-base that was more visible in the Americas but nevertheless industrial innovation up 5%, very solid, driven by 3D experience and cloud with Inovia leading the momentum. We saw several competitive wins across both core and diversification industries and it really highlights the strength of our integrated platform with good momentum with Centric and SOLIDWORKS. SOLIDWORKS performance was broad-based across FUSE, with a unit growth of up double digits. And our traction on AI is very solid with over 40 use cases now available in the SOLIDWORKS portfolio. And this is driving the move to subscription and from cut into simulation and manufacturing. Centrix delivered another strong performance in Q3 with several significant wins. including a global leader in sports merchandising and licensing, as well as a significant US fashion and outdoor brand. And this reinforces our confidence in the Centric business to remain at the forefront of consumer-driven transformation across food and beverage, retail and sports apparel, and it's all augmented by Centric's end-to-end platform, NAI. and we are reaching two important milestones. First, many data improved sequentially and it was flat year-on-year and it's on track to deliver growth from Q4 onwards. The shift to enterprise platform business model is well underway. We are replicating the deal we signed with WCT in Q1. Now in Q3 we signed a significant expansion with Everest. Overall, we are expanding our pipeline of transformational platform agreements across CRO partners, mid-market as well as enterprise clients. This is resulting in a positive impact on renewals and booking scores over the last quarters. And from a solution perspective, it's worth highlighting that patient cloud and our study experience, we completed the IRIS Global Acquisition in the second half of September. And you heard this already from Pascal. So this is an Agro-Global revenue will be reported as part of the Life Sciences product line going forward. The revenue contribution is not material for the third quarter of 2026.
Pascal Daloz
Chief Executive Officer and Chairman
And one more point.
Rouven Bergmann
Chief Financial Officer
With Pascal, I share the excitement to have Ashwini Sanus join and lead our teams across Life Sciences. and I look forward to working with her to reveal and deliver the full potential of our business in this new chapter that we are starting.
Pascal Daloz
Chief Executive Officer and Chairman
So now turning to our cash performance.
Rouven Bergmann
Chief Financial Officer
We have generated strong operating cash flow of year-to-date 1,567,000,000. This is up 20% XFX and up 18% reported. And this was driven by strong operating performance with higher billing activity and good collections. In the third quarter, cash flow from operations was up over 77% on a strong operating cash flow of 1,388,000,000, driven by strong operating cash flow. All of the above resulted in good cash conversion at 111% year-to-date, which is well ahead of last year at this time. Now to complete the picture. Cash and trash equivalents reached 3,814,000,000 at the end of September 2026. Year-to-date operating cash flow has already funded the 1.5 billion Ares Global Acquisition, leaving cash and cash equivalents broadly unchanged. This also includes the repayment of the 0.9 billion bond which was due in September. Our net cash position of 1 billion and 49 million provides the financial flexibility to continue to invest selectively in our growth and value creation levels as we move forward. Now let's turn to our full-year objectives. First of all, let's take a step back. Since we started the year, we have progressively increased our top-line growth rates from 3% in Q1 to 4% in Q2. As we enter into the fourth quarter, it gives us the room to narrow our full-year guidance range from previously 120 million to now 60 million while we are integrating ARIS Global. So what does it mean for the guidance range? For the full year we update our revenue outlook from 3-5% to now 4-5% revenue growth. The new range of 6,399,000,000 to 6,459,000,000 reflects an increase of 103,000,000 to the low end and an increase of 43,000,000 to the high end of the previous range. And with this, our midpoint is increasing by 73 million, which documents our confidence in our 2026 full-year outlook. Now, reflecting this positive momentum, we are also raising the operating margin outlook, which now reflects a range of 32.5% to 32.7% versus 32.2% to 32.6% prior. Finally, 5 to 1 euro 36. Now, let's zoom into the fourth quarter objectives. For the fourth quarter we expect revenue growth of 5-8% and this includes a 2-point contribution to growth from ARES Global. We expect the operating margin in the range of 37.2% to 37.8% with EPS at 42 cents to 43 cents which is up 3-7% xfx. For the exchange rates Q4 guidance now assumes and the tax rate of 17.4% for Q4. So, hence, combining the anticipated growth in Q4, to summarize, combining the anticipated growth in Q4 throughout the year. Now, to finish, let me summarize the key points. We continue to execute on our growth strategy. As you can see, we are delivering sequential improvement Quarter after quarter, and our growth drivers show the strategy is working. The shift to subscription is well underway, and our 3D experience and cloud growth is accelerating. And as we enter Q4 2026 and we look ahead, our focus remains on execution and delivering on our numbers. We continue to advance our growth drivers, accelerating AI, and shape our life scientist business to deliver sustainable growth. We will continue to expand margins and improve cash conversion to generate consistent long-term value for clients, our customers, the company and shareholders. This will be at the center of our upcoming Cabrillo Marketing. So with this, Pascal and I look forward to take your questions. Thank you.
Marie
Investor Relations
We will first take questions from the room and then online.
George Webb
Analyst
Thanks for hosting us in person, it's George from Walt Stanley. A couple of questions. Firstly, on the virtual companions, what you've been seeing over the last quarter in terms of the ramp-up or usage of those different virtual companions. And then the second one, on the agreements that you're doing on the metadata side with WCT and now with Everest, as I understood it from what I think you said, they kind of make it a default platform or a default system of choice. for their trials. How does that work if a sponsor or a drug company comes in and mandates usage of a different platform or a different solution from a different... George for the question.
Pascal Daloz
Chief Executive Officer and Chairman
So I will take the first one and maybe Rouven you can take the second one. So the first one is relatively simple. It's all the customers who move to the latest release. Obviously it's the case for 100% of the one being cloud, on cloud. and for the one who are on-prem, obviously they need to do the upgrade, 30% and 40% of the total install base, whatever it is Sony works or CATIA and 3DEX platform. They are unable with the virtual companions. The second thing is for all of them, what we have done is a discovery offer, because we have to promote the companions, specifically Leo and Aura. for them to play a little bit with it without having to charge something in order to start to build the momentum for 2027. This is where we are currently. It's well received. That's probably the most important thing for me. And again, the 100 strategic customers I was referring to are really the ones where Not only they are using extensively the companions, but they push us to go a step forward of what we can do with it. It's easier to use our applications. LEO could also use applications from the third party. And we have to train LEO to do it. So that was not the number one priority for us when we came with the virtual companions. but very rapidly it became that this is also extremely important for us to basically have this ability if we want to orchestrate you know the full development processes or the full production processes having all those things being connected so that's where we are very lot of startups also in the robotics domain which are probably the one adopting our solutions the fastest because they need to develop the solutions but also they need to test it and the virtual environment is really useful for them to make their AI in a way capable to be embarked into the products.
Rouven Bergmann
Chief Financial Officer
The second part for Medidata and what does it mean for the CROs? Thank you, Georges. Those type of deals we are signing are the enterprise platform deals and what's really important for CROs but also for Our enterprise clients is for them to standardize and the time to first patient in and first patient out of a clinical trial or last patient out, first patient in. So what we are able to bring to them is efficiency. We have an integrated platform. AI is accelerating their workflows, is accelerating evidence generation and they see the benefit of standardizing on our platform. At CDS, Clinical Data Studio is agnostic. It works with any EDC. and that's a huge benefit for CROs and it creates like a platform of platform for us to aggregate and manage all the operations. And I've seen that evidence in customer client discussions with WCT where I was directly involved in Q1 and now with Everest. It's a main driver for those CROs that are growing fast, they're taking market share Interestingly, some of them are also private equity owned, so there is a clear metric behind productivity and outcomes. So, you know, there are large investments they are taking with a clear commitment to results, and we are part of this. And Rouven, the question is also the relationship between the sponsor and the CROs. Yeah, so when a sponsor has a preference, again, first of all, CDS is agnostic. We're not shutting the door, we cannot do that. But the benefit of an integrated platform and reducing the time to first patient in is what's driving the standardization and where we have a strong position to gain market share. So of course we want to increase our share of wallet, our penetration with this approach. But it's an open approach but with clear benefits, I think, to our adoption.
Michael Briest
Analyst, UBS
Thank you for the question. Two from me. The first would be around just in mainstream innovations, the sort of split of performance by solid works or even reverse. And then I guess Pascal, competitive dynamics. There have been some changes announced this quarter and I assume you see more opportunity than threat in that. But can you talk about your game plan, how to sort of capitalise on that? Thank you.
Rouven Bergmann
Chief Financial Officer
Thank you Michael, I take the first one. So for mainstream, SOLIDWORKS performance is very consistent throughout the year. SOLIDWORKS is growing above group level, 6% plus. It varies from quarter to quarter but continuously performing at 6% plus. With also expansion in double digital cross in terms of users that we are winning. In terms of business model transition for SOLIDWORKS to finish these new clients is about one start, which is cloud. And so that's well underway. And it's progressing and increasing. When you look at the mainstream overall between SOLIDWORKS and Centric, Centric growth was very strong in the first six months. We said that it will start to slow down a little bit in the H2, but Q3 was again a very good quarter. We indicated around 15% growth, it was better than that. And we have also good visibility and pipeline for the fourth quarter. So overall, Centric is growing at a higher rate than SolidWorks in the mainstream segment.
Pascal Daloz
Chief Executive Officer and Chairman
And mainstream overall consolidation, which is happening in the industrial software, is a very interesting one, by the way. And there are few takeaways. The proposal to acquire PTC by Schneider has to be put in front of Siemens. But at the end, that's what they try to do, is to link the IT space with the IoT space. It has been the strategy followed by Siemens at the time when they acquired UGS. It was also the key. Why? It's a different game we are following. We do not want to create a strong connection between the world of the controllers, of the automatisms. With the world of the PLM, we want to create a tighter integration between the world of creations, the world of the life cycle management with AI and intelligence. So, and when you think about it, we are only a two pure play now on the market. Right? I remember a few years ago, we were, I mean, a significant number of competitors. Having this agility and flexibility to bring these innovations. Now if you look at many of them are part of the big industrial conglomerates or others are part now and deeply linked with the EDA space for the specific for the simulation. So what does it mean? It means what I started to share with you is how we are building the 3DEXPAN platform to become agentics. I think having PTC acquired by Anthropic would have been much more a constraint or a problem for us. So that's the reason why again at the strategic level my view this is cleaning the landscape, this is giving us the agility like a pure play has and it's giving us the Basically, the unique positioning we are looking for. Now, there are also direct consequences on this. As you may know, Schneider is strong on the process industry more than on discrete manufacturing, where PTC has the footprint. So this is obviously opening, you know, the competitive position. And you can count on us to put something in front. The big device, for example, or the fashion industry. Remember, PTC is one of the competitors with windshield against Centric. This is opening this market. And last but not least, PTC was the last US player. And there are certain sensitive domains in the US where being US native, are European native, you do not have the same access. My view, this is also reopening some doors for us.
Rouven Bergmann
Chief Financial Officer
More to say.
Pascal Daloz
Chief Executive Officer and Chairman
Michael.
Frederic Boulan
Analyst, Bank of America
Thanks. A question from Fred from Bank America. Commercial and pricing strategy. I know it's early days, but it would be great to understand any KPIs or insights you can share on and to a degree, we can start to see contribution to revenue next year. And then second, from a cost perspective, how should we think about AI investments in terms of R&D, et cetera, OPEX, CAPEX, versus AI efficiencies that you can actually leverage? Thank you. Thank you.
Rouven Bergmann
Chief Financial Officer
Thank you, Fred. I trust that one. So on the AI pricing and monetization, How do we track that? You see, right now we are more in a project mode, an enter mode. It's important to gain footprint and momentum to show the progress that can be achieved. But we already said at our last Capital Market Day that we have a financial objective for revenue that we will be generating with our Gen 7 portfolio, 3D universes. and in 2027 will be the first year because at the end what we are achieving is client commitments and those client commitments will be around our 3DEXPERIENCE agentic platform and the 3DEXPERIENCE agentic platform continues to be user-based. It can be humans, it can be agents, it's a user-based platform that offers skills and domains and access to knowledge. and agents we know are much more efficient in consuming and materializing knowledge and know-how so the usage on our platform would be much much larger than what a usage typically is for humans so that part would be measured based on the units of work the tokens consumption with virtual companions and generative experiences so those two dimensions continue to expand on a user-based agentic platform and the agentic capability to consume all the knowledge and know-how and the skills and domains and for that we already released the virtual companion competencies that represent about 50% of our portfolio and we are advancing very fast to complete that to north of 80%. So that's all full in motion and as you see evidence with the 100 projects we have. So I think from that perspective we are ready to execute. Should I cover the cost part? From a cost standpoint, I think the best way to, you can measure, you can look at this in terms of capex spent, of course. When you look at our year-to-date performance, we spent roughly 100 million, a little bit more in CapEx, so not materially different than last year. So there's no exposure in 2026. However, I expect that in our R&D organization, we have a model today in place that allows us to trade off token consumption AI across our expense categories. Our current OPEX is scoring less than 3% on a normalized basis. There could be some volatility quarter to quarter, but overall I think we are very well set on around 3%. And that gives us room for margin expansion. but at the same point in time room to continue to invest because that is very important to ensure that this growth wave that we now have in front of us we can execute and we don't have to catch up. And that's the mindset we have and I think we're in a good position. Maybe I could add a few things.
Pascal Daloz
Chief Executive Officer and Chairman
We have deployed the agentic approach across the development teams. We have deployed Cursor and all the 12,000 engineers we have within the company, they are using Cursor extensively. How do we see the benefit of this? Of course, you have all the productivity KPIs you can imagine, the time to write the calls, the time to do the tests. But you, if you want to modelize it, I think the best way is to look at the increase of the headcount.
Rouven Bergmann
Chief Financial Officer
500 people.
Pascal Daloz
Chief Executive Officer and Chairman
This year we divided by two. So gross is around 2,000 people and net slightly below 1,000 people. That's really how we are basically taking the benefit of it. We do more with a little bit less people we need to hire in order to fulfill the capacity.
Charlie Brennan
Analyst, Jefferies
Hi, it's Charlie here from Jefferies. Just two questions from me as well. Firstly, can I touch on the guidance? In Q3, you outperformed the midpoint of expectations by about a percentage point. That's roughly 15 million of revenue. You'll get an incremental 40 million of revenue from ARIS Global in Q4. Taking those together, that's about 55 million of incremental revenue. About a 25 million downgrade to Q4. Does that mean that some deals moved from Q4 into Q3 or is that just an abundance of caution to make sure you continue to deliver on Q4? And then secondly, a slightly technical question actually. You're reporting ARR growth of six but recurring revenue growth of three. What are the technical levers that account for that disconnect? I would have thought recurring revenue growth would be closer to ARR growth. How should we think about that three percentage point gap as we move into 2027? Thank you.
Rouven Bergmann
Chief Financial Officer
So, first of all, let me give you a clearer picture on the guidance. So, yes, a few things I can confirm, a few things are not correct what you said. We over-performed Q3 by roughly 15 million. I can confirm that. The number that you have in mind for Aras Global is not correct. It's more like... Two points of growth in Q4 is not 40 million, it's less than that. We talk about 30 to 35 million of contribution to the fourth quarter. So if you put that together, we are raising our midpoint by about 73 million. The remaining delta is pretty much currency effective. So that's the first part. I want to be very clear. The Q1, Q2, Q3 performance puts us clearly on track to hit our midpoint. plus the Ares Global contribution in the fourth quarter, which is in the range of 30 to 35 million euros, brings us the visibility that we now need in order to reduce the range from 120 to 60 million, raise the low end, increase the high, and raise the midpoint by 70 million. So it's really a mix of Ares Global and FX adjustment. but it's not a downgrade of our organic perspective. That's not the track record we have set for the first nine months of the year and the visibility we have for the fourth quarter. I think you hear our confidence and our conviction on this. So now let's move to ARR.
Charlie Brennan
Analyst, Jefferies
I said two points of growth to Q4, okay? I said 175 million US dollar.
Rouven Bergmann
Chief Financial Officer
That was the number, it's not 160 million, it's based on the currency that we assume in our guidance, okay?
Charlie Brennan
Analyst, Jefferies
You are putting out the numbers, I need to correct them.
Rouven Bergmann
Chief Financial Officer
Let's go through AR. So for AR, you're right, the current revenue growth has 3% versus a 6% rate. When you look at the definition of AR, what's important to understand is it is less so in maintenance but really in subscription revenue. Always some seasonality because of timing of renewal as multi-year subscriptions have an upfront part in our revenue recognition and that can skew the subscription number and that creates some volatility in year-over-year comparison. So that is not in our ARR reflected because the ARR always takes a 12 months run rate based on the order entry. So all the orders that we have received on the 12 months value going forward. It's a forward-looking metric. and that has been really consistent now for a few quarters now with 6% but what's really happening inside the ARR is that the share of subscription is increasing steadily one point per quarter since Q3 2025 and while the maintenance portion is declining and also because the maintenance growth is coming down from around 3% to 0% and so this is accelerating of course the share gain of subscription overall as this mix is shifting. So again I think best to summarize the revenue number is a backwards looking number where the maintenance is pretty evenly recognized as the ARR looks forward, right? While subscription has more volatility and now with the ARR we really straight line that. So you have a clear 12 months run rate of mid-teens growth on subscription. That is the difference. There are differences in the way it is calculated and we think we are very explicit about that. And of course we expect as the share of subscription is increasing that the recurring revenue recognized will approximate more towards the ARR while the ARR is accelerating.
Balaji Tirupati
Analyst, Citi
and Balaji Tirupati from Citi. Two questions from my side, if I may. Firstly on competitive dynamics, how do you see the evolution of AI labs in terms of their model capabilities, including in design, as well as acquisitions to extend their capabilities? For example, the orchestra by acquisition by OpenAI, it would appear the vision around Thank you for the question.
Pascal Daloz
Chief Executive Officer and Chairman
But best way to answer to it is orchestration is not science. You need both. So why this is important because orchestrating the usage and the different apps in a coordinated workflow is necessary since when you want to improve the productivity of the existing things. If you want to create new things, you need to combine the two. And in a way, This acquisition, my view, is much more utopic for Viva than for us. Because they are the workflows. We are the science. That's the biggest difference for me. Now, what does it mean, nevertheless? If you could combine the two together, you are creating a unique position. And that's what we do. That's really what we do. So, do not underestimate that When you do an adjunct approach you have several things. Obviously you have the harnessing capability. The harnessing is really how you connect the different things together. But also you need the reasoning. So the reason why we have different companions is because all of them have a different reasoning. An engineer does not have the same reasoning as a scientist. does not have the same reasoning than a doctor. That's where we are making a difference. The second thing, you need the knowledge base. And the knowledge base is the virtual twin. If you want to give AI the context of everything you do, you need the virtual twin. Remember my story with Tesla driving the virtual car in the virtual city. but basically using the real algorithms which is now embarked into the core. So that's the virtual tree, the knowledge base. Then after you need the application. I think we have the application. We have a pretty extensive set of applications to cover the entire life cycle. And last but not least, you need the models. Whatever the frontier model or the open-weight model. And here is an interesting thought. I know you have seen, by the way, Jensen Wang last week. He made a very comprehensive explanation about this. You could use both. And by the way, the world is going to consume the quality of the results. That's point number one. And point number two, if you have an open weight model and you have the data sets, you could exceed the performance of the frontier model. I repeat, if you have the open-weight model like Nemotron or others, in conjunction with a proper dataset to train them, you could exceed what a frontier model can do. So this is our strategy. And this is how we are differentiating ourselves. So on the quality of the harnessing, the quality of the reasonings, the knowledge base with the twins, the deep set of applications, and how to fine-tune the open wake model to be basically extremely precise on certain use cases. And I think with this, we have enough to differentiate ourselves.
Rouven Bergmann
Chief Financial Officer
Good, so to your second part on the cache. And so first of all, we are very pleased with the progress of our performance on operating cache flow and cache conversion. Our target was in 2026 to be back at the level of 2024 after some headwinds we were facing last year. Now we are ahead of this target. Take a look into the fourth quarter. There are a few puts and takes for the fourth quarter cash flow. But right now I'm looking at a performance that is similar to 2025. and if you do that we are well ahead of the target that we have set with 84 percent and then that gives us a new starting point entering into 2027 and clearly here we are we will be you know right now I see us more in that range of 85 to 90 percent of cash conversion and we will move further upwards That's the simple answer.
Marie
Investor Relations
I'll take one more question online. Thank you.
Conference Operator
Operator
To ask a question, you will need to press star 1 and 1 on your telephone and wait for your name to be announced. To return your question, please press star 1 and 1 again. Our last question for today is Just one moment. It comes from Doran Dor from Cap-le-Chevre. Please go ahead.
Laurent Daure
Analyst, Kepler Cheuvreux
Yeah, good morning, gentlemen. Thank you for taking my questions. I have two, in fact. The first is on Medidata and the return to work, so I was speaking for the specialty at Renewals. So I was wondering, on the side of the much better bookings you had recently, All those headwinds are going to move in the coming quarters, and whether for 2027 we will have less headwind offsetting the new winds. And my second question is back to your guidance for the rest of the year. You've been improving the growth rate by one point every quarter, but when I take the midpoints of your fourth quarter guidance, on slightly easier counts. It's a bit softer than Q3. So is there anything specific you should be aware or any challenges you're going to face in the first quarter or just a bit of cautiousness? Thank you.
Rouven Bergmann
Chief Financial Officer
Maybe I start with the second question. Thank you, Laurent. Look, the guidance is always arranged. You can take the midpoint. Of course you're right and that gives us confidence in the performance here today. We have delivered midpoint or better than midpoint and on an organic basis the 3-6% puts us squarely at the midpoint of our guidance that we have set at the beginning of the year and that has been our objective. And for that, there is a range, right? And there is an opportunity to do better than that, but I think the midpoint is very secure and we have clear visibility towards that. Do you take the first question or should I continue?
Pascal Daloz
Chief Executive Officer and Chairman
Please take it. To MediData,
Rouven Bergmann
Chief Financial Officer
and that also has impacted still impacts our 2026 performance but as we enter into 2027 we have a much cleaner slate of growth that we where those headwinds of prior renewals are more in our base than they were in 2026 but more importantly it seems it's to highlight that the growth bookings performance has been very consistent year to date to build our order entry and starting point for 2027. You know, very different than when we were in 26 with growth. And we are, as I mentioned before, Q2 was minus 4% for life scientists. We are now plus 1, so we are improving by 5 points. For MediData, it's about 3 points of improvement plus. The next quarter, we are expecting an improvement of sequentially of about 2 points. and then we enter into 2027 where we should expect further improvement in terms of growth. That's the trajectory on which and that will also be the guidance philosophy for 2027 will be very much based on the order entry and our backlog that we already have in place to make sure it's a baseline forecast and we can build growth on top.
Laurent Daure
Analyst, Kepler Cheuvreux
Okay, thank you.
Rouven Bergmann
Chief Financial Officer
Thank you, Laurent.
Conference Operator
Operator
Thank you. That is all the time we have for questions today. I'll hand the call back to the speakers for closing remarks.
Pascal Daloz
Chief Executive Officer and Chairman
So, thank you again for all the questions. And to wrap up, let me leave you with three key messages. The first one, I think, we are delivering. And we consider we have a strong Q3. We must continue to expand our use of 3D experience and the cloud. I mean the numbers speak by themselves. The second thing I think bringing AI into the real world with 3D universes, our agentic platform, the industry world model, the virtual twins. I think we are helping the industry to put AI in work, in the real work environments. and this is I think the most important thing because all of our customers are becoming AI native. The third point, I think we are making important steps and progress in life sciences. You know, Harris Global joining us, Dr. Zenouz joining us as well to take the leaderships and to foster the ambitions to create them. These priorities are closely connected They are definitively helping us to build a stronger customer relationship, focus on our investment and create value on the long term. So that's why we are building together with our customers and employees. And I think this is for the benefit also of you, other shareholders. So we look forward to sharing more games with you at our Capital Market Day on Paris, November the 17th. Remember the dates.
Rouven Bergmann
Chief Financial Officer
and hopefully we will have the pleasure to see all of you.
Pascal Daloz
Chief Executive Officer and Chairman
Thank you and hope to see you on the road and no later than the Capital Market Day. Goodbye. Thank you.